845884-29-9

Upstream product

• 845884-28-8 4-[4-(2-hydroxy-ethyl)-benzyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 143817-58-7 N-(tert-butoxycarbonyl)-2,2-dimethyl-4-(4-hydroxyphenyl)-1,3-oxazolidine 
• 845884-27-7 2,2-dimethyl-4-(4-vinyl-benzyl)-oxazolidine-3-carboxylic acid tert-butyl ester 
• 386207-30-3 2,2-dimethyl-4-(4-trifluoromethanesulfonyloxy-benzyl)-oxazolidine-3-carboxylic acid tert-butyl ester 

Downstream Products

• 845884-30-2 4-(4-carboxymethyl-benzyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 536739-84-1 (S)-4-[4-((1R,2S,3R)-2,3-Bis-benzyloxy-1-benzyloxymethyl-pent-4-enyloxycarbonylmethyl)-benzyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

RCM-based synthesis of a variety of β-C-glycosides and their in vitro anti-solid tumor activity

(Chemical Equation Presented) The synthesis of a number of biologically relevant C-glycosides has been carried out through the use of an esterification-ring-closing metathesis (RCM) strategy. The required acid precursors were readily prepared via a number of standard chemical transformations followed by dehydrative coupling of these acids with several olefin alcohols 1 to yield the precursor esters 3 in excellent yield. Methylenation of the esters 3 was followed by RCM and in situ hydroboration-oxidation of the formed glycals to furnish the protected β-C-glycosides 6 in good overall yield. Several examples were converted to the corresponding C-glycoglycerolipids 17 and subsequently screened against solid-tumor cell lines for in vitro differential cytotoxicity.